MedDataX Logo

Pregnenolone as a Treatment for Cannabis Intoxication

NCT ID: NCT07216690

Last Updated: 2025-11-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

PHASE2

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2026-01-05

Study Completion Date

2029-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The present study will characterize the ability of pregnenolone to reverse the acute intoxication and associated symptoms of cannabis. Healthy adults with a history of cannabis use will be recruited to participate in a placebo-controlled, within-subject crossover study at Johns Hopkins Behavioral Pharmacology Research Unit (BPRU). By clarifying the ability of pregnenolone to reverse cannabis intoxication symptoms, this study will pave the way for larger clinical studies that provide a foundation for the development of future CB1-receptor NAM medications that could be applied in emergency situations and potentially validate pregnenolone as a treatment for cannabis intoxication.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This human laboratory study will characterize the ability of pregnenolone to reverse the acute cannabis intoxication using measures of subjective drug effects, cardiovascular responses, and cognitive performance. Participants (n=16) will complete four double-blind, randomized, outpatient sessions. In each session, participants will self-administer cannabis containing either 0 mg THC (placebo) or 25 mg THC (active) via an oral route of administration. Ninety minutes after cannabis administration, participants will self-administer two oral capsules containing either 0 mg pregnenolone or 250 mg pregnenolone for a total of either 0 mg, 250 mg, or 500mg pregnenolone. Assessments will include subjective drug effect instruments, a battery of cognitive and psychomotor performance tasks, and physiological measures. Sessions will be conducted at a target rate of once per week. Results from this study of pregnenolone could have far-reaching clinical implications: not only would results provide conceptual support for NAMs as treatments for cannabis intoxication but may posit pregnenolone itself as a novel pharmacotherapeutic that could reduce the burden of ineffective and potentially harmful medications currently used in the treatment of cannabis intoxication in emergency settings. If pregnenolone is shown to be effective, additional drug development can be done to determine the best formulation, dose, and route of administration for maximal clinical benefit. Should pregnenolone not reverse THC intoxication completely, development of analogs with greater efficacy can be explored.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cannabis Intoxication

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

cannabis pregenolone cannabis intoxication THC delta-9-thc CB1 receptor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Randomized, controlled, within subjects
Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors
Double blind, double dummy

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo Brownie and Capsules

Placebo brownie, 0mg THC; two 0 mg pregnenolone capsules

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo capsule, 0mg

Placebo brownie

Intervention Type DRUG

Placebo brownie, 0mg THC

Cannabis/THC brownie and Placebo Capsules

25mg Cannabis/THC Brownie; two 0 mg pregnenolone capsules

Group Type PLACEBO_COMPARATOR

Cannabis

Intervention Type DRUG

Cannabis brownie, 25mg THC

Placebo

Intervention Type DRUG

Placebo capsule, 0mg

Cannabis/THC Brownie and Pregnenolone, low dose

25mg Cannabis/THC Brownie; one 250 mg pregnenolone capsule and one 0 mg pregnenolone capsule

Group Type EXPERIMENTAL

Cannabis

Intervention Type DRUG

Cannabis brownie, 25mg THC

Pregnenolone 250 mg

Intervention Type DRUG

Pregnenolone, low dose, one 250mg pregnenolone capsule and one 0 mg pregnenolone capsule

Cannabis/THC Brownie and Pregnenolone, high dose

25mg Cannabis/THC Brownie and two 250 mg pregnenolone capsules

Group Type EXPERIMENTAL

Cannabis

Intervention Type DRUG

Cannabis brownie, 25mg THC

Pregnenolone 500 mg

Intervention Type DRUG

Pregnenolone, high dose, two 250 mg pregnenolone capsules

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cannabis

Cannabis brownie, 25mg THC

Intervention Type DRUG

Pregnenolone 250 mg

Pregnenolone, low dose, one 250mg pregnenolone capsule and one 0 mg pregnenolone capsule

Intervention Type DRUG

Pregnenolone 500 mg

Pregnenolone, high dose, two 250 mg pregnenolone capsules

Intervention Type DRUG

Placebo

Placebo capsule, 0mg

Intervention Type DRUG

Placebo brownie

Placebo brownie, 0mg THC

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

delta-9-tetrahydrocannabinol THC delta-9-THC Pregnenolone Pregnenolone

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Ages 18-65
* Good general health based on screening procedures (e.g. physical exam, blood testing, psychiatric evaluation)
* Systolic blood pressure \<140 mm Hg, diastolic blood pressure \< 90 mm Hg, and heart rate \<110 bpm at screening and at baseline for dosing session
* Body mass index (BMI) in the range of 18 to 36 kg/m2
* Cannabis use within the past three years but none in the month prior to the first test session
* Negative urine test for illicit substance use and negative breath alcohol test (0% breath alcohol concentration) at screening and before study sessions

Exclusion Criteria

* Use of psychoactive substances (aside from nicotine, caffeine, and alcohol) in the month prior to study initiation
* Current use of over the counter (OTC) drugs, supplements/vitamins, or prescription medications that, in the opinion of the investigator or medical staff, will impact the participant's safety.
* Self-report clinically significant cardiovascular conditions, including coronary artery disease, stroke, angina, uncontrolled hypertension, arrhythmias (e.g. atrial fibrillation), heart valve placement, or TIA in the past year.
* History of hormone-sensitive conditions, including but not limited to gynecologic cancers (breast, ovarian, uterine, etc), endometriosis, uterine fibroids, thyroid, pituitary and/or adrenal syndromes, polycystic ovarian syndrome, etc.
* Epilepsy or a history of seizures
* Any of the following laboratory values during screening or upon admission:

* AST \> 165 U/L (normal range 19-55)
* ALT \> 216 U/L (normal range 19-72)
* Alkaline phosphatase \> 378 U/L (normal range 38-126)
* Total bilirubin \>2.5 mg/dl (normal values=0.3-1.0 mg/dL)
* Glomerular filtration rate (EGFR) \< 45 (normal values \>60)
* Current or past history of meeting DSM-5 criteria for schizophrenia spectrum or other psychotic disorders, or bipolar I or II disorder
* Other unstable and/or compromising medical or psychiatric conditions based on clinical interview and/or MINI results that would interfere with participant safety as determined by study physician, including suicidal ideation and/or attempt, psychosis
* Previous diagnosis and treatment for Cannabis Use Disorder
* Urine drug screen indicating the presence of substances including amphetamines, barbiturates, benzodiazepines, cocaine, opioids (including fentanyl), PCP, and THC at screening and prior to study sessions
* Breath screen indicating presence of alcohol at screening and prior to study sessions
* Women who are pregnant (as indicated by a positive urine pregnancy test assessed at intake and before each drug session) or nursing
* Women who are of childbearing potential and sexually active who are not practicing an effective means of birth control including oral contraceptives, progestin implant, transdermal birth control patch, intrauterine device (IUD), vaginal ring, and/or regular use of condoms or diaphragm.
* Breath alcohol screens indicating presence of alcohol at screening and prior to study sessions
* SBP \>/= 140, DBP \>/= 90, or pulse \>/=100 during screening and/or prior to dosing session
* Has donated blood within 30 days of the study
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute on Drug Abuse (NIDA)

NIH

Sponsor Role collaborator

Johns Hopkins University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

David Wolinsky, MD

Role: PRINCIPAL_INVESTIGATOR

Johns Hopkins University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Johns Hopkins University School of Medicine, Behavioral Pharmacology Research Unit

Baltimore, Maryland, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

David Wolinsky, MD

Role: CONTACT

Phone: (646) 572-6959

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

David Wolinsky, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R21DA063854

Identifier Type: NIH

Identifier Source: secondary_id

View Link

IRB00526530

Identifier Type: -

Identifier Source: org_study_id